DK0932411T3 - Præparater indeholdende immunogene molekyler og granulocyt-makrofagkolonistimulerende faktor som en adjuvans - Google Patents

Præparater indeholdende immunogene molekyler og granulocyt-makrofagkolonistimulerende faktor som en adjuvans

Info

Publication number
DK0932411T3
DK0932411T3 DK97904876T DK97904876T DK0932411T3 DK 0932411 T3 DK0932411 T3 DK 0932411T3 DK 97904876 T DK97904876 T DK 97904876T DK 97904876 T DK97904876 T DK 97904876T DK 0932411 T3 DK0932411 T3 DK 0932411T3
Authority
DK
Denmark
Prior art keywords
granulocyte
adjuvant
stimulating factor
macrophage colony
preparations containing
Prior art date
Application number
DK97904876T
Other languages
English (en)
Inventor
Elke Jager
Alexander Knuth
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of DK0932411T3 publication Critical patent/DK0932411T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001139—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK97904876T 1996-02-09 1997-01-28 Præparater indeholdende immunogene molekyler og granulocyt-makrofagkolonistimulerende faktor som en adjuvans DK0932411T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/598,909 US6096313A (en) 1996-02-09 1996-02-09 Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
PCT/US1997/001249 WO1997028816A1 (en) 1996-02-09 1997-01-28 Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant

Publications (1)

Publication Number Publication Date
DK0932411T3 true DK0932411T3 (da) 2003-08-18

Family

ID=24397438

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97904876T DK0932411T3 (da) 1996-02-09 1997-01-28 Præparater indeholdende immunogene molekyler og granulocyt-makrofagkolonistimulerende faktor som en adjuvans

Country Status (12)

Country Link
US (1) US6096313A (da)
EP (1) EP0932411B1 (da)
JP (1) JP2000506518A (da)
AT (1) ATE243525T1 (da)
AU (1) AU723147B2 (da)
CA (1) CA2244867C (da)
DE (1) DE69723092T2 (da)
DK (1) DK0932411T3 (da)
ES (1) ES2196305T3 (da)
PT (1) PT932411E (da)
WO (1) WO1997028816A1 (da)
ZA (1) ZA97858B (da)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7901693B2 (en) * 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US7144581B2 (en) * 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030235557A1 (en) * 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030039635A1 (en) * 1998-09-30 2003-02-27 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) * 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en) * 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
ID30407A (id) 1999-05-13 2001-11-29 American Cyanamid Co Formulasi-formulasi kombinasi bahan penambah
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
TW581709B (en) 1999-10-22 2004-04-01 Asahi Kasei Corp Heat-resistant microporous film
CA2388301C (en) 1999-10-22 2011-01-04 Aventis Pasteur Limited Modified gp100 and uses thereof
US6911204B2 (en) 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
SG143058A1 (en) * 2000-08-11 2008-06-27 Favrille Inc Method and composition for altering a t cell mediated pathology
WO2002038177A2 (en) * 2000-11-10 2002-05-16 Wyeth Holdings Corporation Adjuvant combination formulations
US7553494B2 (en) * 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EP1552878A4 (en) * 2002-10-18 2006-03-22 Asahi Kasei Pharma Corp MICROPOR SE HYDROPHILIC MEMBRANE
PT2359841E (pt) 2003-01-30 2015-02-10 Survac Aps Péptidos derivados de survivina e a sua utilização
JP4926714B2 (ja) 2003-11-19 2012-05-09 サーバック エーピーエス Ｂｃｌ−２ファミリ−に属するタンパク質およびそのフラグメント、ならびに癌患者におけるそれらの使用
US20050260217A1 (en) * 2004-03-04 2005-11-24 Corixa Corporation Co-encapsulated WT1 polypeptide and immunostimulant microsphere formulations and methods thereof
EP1838348B1 (en) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanized amyloid beta antibodies for use in improving cognition
DK1853305T3 (da) 2005-02-04 2014-12-01 Survac Aps Survivin-peptidvaccine
SI1760089T1 (sl) * 2005-09-05 2009-12-31 Immatics Biotechnologies Gmbh S tumorjem povezani peptidi, ki se veĹľejo na molekule humanega levkocitnega antigena (HLA) razreda I ali II in ustrezno cepivo proti raku
CA2523032A1 (en) 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
GB2432722A (en) * 2005-11-25 2007-05-30 Seiko Epson Corp Electrochemical cell and method of manufacture
GB2432723B (en) * 2005-11-25 2010-12-08 Seiko Epson Corp Electrochemical cell and method of manufacture
GB2432721B (en) * 2005-11-25 2011-06-22 Seiko Epson Corp Electrochemical cell structure and method of fabrication
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
NZ582823A (en) * 2007-07-27 2012-04-27 Immatics Biotechnologies Gmbh Composition of tumour-associated peptides and related anti-cancer vaccine
ES2498040T3 (es) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
ES2588705T3 (es) * 2007-09-27 2016-11-04 Immunovaccine Technologies Inc. Uso de liposomas en un vehículo que comprende una fase hidrófoba continua para la entrega de polinucleótidos in vivo
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
DK2280721T3 (da) 2008-04-17 2018-01-29 Io Biotech Aps Indoleamin-2, 3-dioxygenasebaseret immunterapi
CA2723918C (en) 2008-06-05 2018-01-09 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
EP2638060A2 (en) 2010-11-10 2013-09-18 Laboratorios Del Dr. Esteve, S.A. Highly immunogenic hiv p24 sequences
EP2492279A1 (en) 2011-02-25 2012-08-29 Laboratorios Del. Dr. Esteve, S.A. Rapid immunogen selection method using lentiviral display
EP2546358A1 (en) 2011-07-15 2013-01-16 Laboratorios Del. Dr. Esteve, S.A. Methods and reagents for efficient control of HIV progression
IN2014CN02581A (da) 2011-10-06 2015-08-07 Immunovaccine Technologies Inc
ES2918580T3 (es) 2011-10-17 2022-07-19 Io Biotech Aps Inmunoterapia basada en PD-L1
WO2013060328A1 (en) 2011-10-26 2013-05-02 Herlev Hospital Ikb based immunotherapy
EP2606897A1 (en) 2011-12-22 2013-06-26 Laboratorios Del. Dr. Esteve, S.A. Methods and compositions for the treatment of diseases caused by enveloped viruses
EP2617434A1 (en) 2012-01-20 2013-07-24 Laboratorios Del. Dr. Esteve, S.A. HIV-1 integrase deficient immunogens and methods for loading dendritic cells with said immunogens
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
EP2698377A1 (en) 2012-08-17 2014-02-19 Laboratorios Del. Dr. Esteve, S.A. Enhanced rapid immunogen selection method for HIV gp120 variants
EP2703482A1 (en) 2012-09-04 2014-03-05 Laboratorios Del. Dr. Esteve, S.A. VSV-HIV viral particles lacking reverse transcriptase functionality and therapeutic applications thereof
EP2886126B1 (en) 2013-12-23 2017-06-07 Exchange Imaging Technologies GmbH Nanoparticle conjugated to CD44 binding peptides
PL3193917T3 (pl) 2014-09-17 2022-01-17 Io Biotech Aps Kompozycje szczepionek zawierające 2,3-dioksygenazę tryptofanową lub jej fragmenty
IL257940B (en) 2015-09-16 2022-08-01 Herlev Hospital Vaccines that include the CC motif. Chemokine 22 or fragments thereof
EP3147364A1 (en) 2015-09-28 2017-03-29 Institut d'Investigacions Biomédiques August Pi i Sunyer (IDIBAPS) Antiviral agents comprising an oligonucleotide-lipid conjugate forming g-quadruplex
CN109803674A (zh) 2016-06-10 2019-05-24 Io生物技术公司 Calr和jak2疫苗组合物
EP3275462A1 (en) 2016-07-27 2018-01-31 Fundació Privada Institut de Recerca de la SIDA-Caixa Virus-like particles with high-density coating for the production of neutralizing antibodies
CN113924114A (zh) 2019-05-22 2022-01-11 吉利德科学公司 Tlr7调节化合物和hiv疫苗的组合
US20220226459A1 (en) 2019-05-22 2022-07-21 Aelix Therapeutics, S.L. Dosage regimens for vaccines
AU2020384323A1 (en) 2019-11-14 2022-06-02 Aelix Therapeutics, S.L. Dosage regimens for vaccines
WO2022017895A1 (en) 2020-07-21 2022-01-27 Rhovac Aps Treatment of residual disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9304089A (es) * 1992-07-08 1994-01-31 Schering Corp Uso de gm-csf como una vacuna adyuvante.
US5519117A (en) * 1992-12-22 1996-05-21 Ludwig Institute For Cancer Research Isolated, tyrosinase derived peptides and uses thereof
US5620886A (en) * 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
US5478556A (en) * 1994-02-28 1995-12-26 Elliott; Robert L. Vaccination of cancer patients using tumor-associated antigens mixed with interleukin-2 and granulocyte-macrophage colony stimulating factor
US6080409A (en) * 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
AU3889997A (en) * 1996-08-16 1998-03-06 Johns Hopkins University School Of Medicine, The Melanoma cell lines expressing shared immunodominant melanoma antigens nd methods of using same

Also Published As

Publication number Publication date
ZA97858B (en) 1997-08-04
CA2244867A1 (en) 1997-08-14
AU723147B2 (en) 2000-08-17
US6096313A (en) 2000-08-01
PT932411E (pt) 2003-11-28
DE69723092T2 (de) 2003-12-18
EP0932411A4 (en) 2001-09-26
WO1997028816A1 (en) 1997-08-14
DE69723092D1 (de) 2003-07-31
EP0932411A1 (en) 1999-08-04
AU1755297A (en) 1997-08-28
EP0932411B1 (en) 2003-06-25
JP2000506518A (ja) 2000-05-30
ES2196305T3 (es) 2003-12-16
CA2244867C (en) 2003-09-09
ATE243525T1 (de) 2003-07-15

Similar Documents

Publication Publication Date Title
ZA97858B (en) Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant.
AU595192B2 (en) Benzonaphthalene derivatives, a process for their preparation and their use in therapeutic and cosmetic compositions
AU640137B2 (en) Novel arylpyridazines, their manufacture, use and medicaments containing them
CA2274074A1 (en) Novel compounds with analgesic effect
AU669122B2 (en) New pyrazine derivatives, their preparation and their use
PT758248E (pt) Formulacoes para o factor ix
EP0627926A4 (en) PEPTIDYL DERIVATIVES USEFUL AS INTERLEUKIN-1-g CONVERTING ENZYME INHIBITORS (b).
MY101791A (en) New benzimidazole derivatives
IL78272A0 (en) Pharmaceutical compositions comprising azolylmethyl-oxiranes for the treatment of viral diseases
MY100343A (en) Amide derivative and external medicament comprising same
ATE188965T1 (de) Neue pyrazincarboxamidderivate, ihre herstellung und ihre verwendung in arzneimitteln
ATE311908T1 (de) Orale verabreichung von chemisch modifizierten proteinen
AU5142093A (en) Tissue protective and regenerative compositions
GR3017128T3 (en) Treatment of hiv infections and compounds useful therein.
ES2054902T3 (es) Para-aminofenoles 3-sustituidos, su procedimiento de preparacion, su empleo en la tincion de fibras queratinicas y compuestos intermedios utilizados en el procedimiento de preparacion.
CA2215470A1 (fr) Composes biaryles heterocycliques, compositions pharmaceutiques et cosmetiques les contenant et utilisations
ATE173252T1 (de) Arylmorpholine, herstellung und verwendung
AU617036B2 (en) Phenylhydrazones, the manufacture thereof and therapeutic and cosmetic compositions prepared therefrom
CA2095352A1 (en) Compositions containing psyllium
AU4482985A (en) Pyrro-1-yl-phenyl-dihydropyridazones
CA2100720A1 (en) Medicinal composition comprising tcf-ii
ES553207A0 (es) Un procedimiento para la preparacion de una octahidroindolizina
AU7336687A (en) Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
AU586557B2 (en) 1,4-dihydropyridine derivatives, process for their preparation and medicaments containing these compounds
NZ217281A (en) Phenyl ether derivatives and pharmaceutical compositions